Xeris Biopharma Holdings, Inc. (XERS) stock
XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.99+0.19 (+1.13%)
Close on Nov 18, 2026Market cap $3.10BP/E –Yield –
Xeris Biopharma pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Xeris Biopharma's pe ratio was 161.6× on Jul 31, 2026.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jul 31, 2026 | 161.6× | – |
See a number that looks wrong?